盆炎消止痛Ⅰ號(hào)方與坤復(fù)康片聯(lián)合治療慢性盆腔炎的臨床對(duì)比研究

鐘鳳嬌

【摘要】 目的：觀察盆炎消止痛Ⅰ號(hào)方聯(lián)合坤復(fù)康片治療慢性盆腔炎的臨床療效。方法：選取本院2015年11月-2016年8月收治的慢性盆腔炎患者86例，按數(shù)字奇偶法將其分為觀察組和對(duì)照組，每組43例。對(duì)照組使用坤復(fù)康片治療，觀察組在坤復(fù)康片的基礎(chǔ)上聯(lián)合盆炎消止痛Ⅰ號(hào)方進(jìn)行治療。治療期間觀察兩組臨床癥狀，記錄盆腔炎性包塊面積和血液流變學(xué)指標(biāo)變化；觀察兩組治療過程中不良反應(yīng)發(fā)生情況；比較兩組治療總有效率。結(jié)果：治療前，兩組盆腔炎性包塊面積和血液流變學(xué)指標(biāo)比較，差異均無統(tǒng)計(jì)學(xué)意義（P>0.05）；治療后，兩組盆腔炎性包塊面積和血液流變學(xué)指標(biāo)均有所降低，觀察組盆腔炎性包塊面積[（4.30±2.23）cm2]和血液流變學(xué)指標(biāo)[（5.66±1.37）mm/h]比對(duì)照組[（8.66±2.32）cm2、（11.27±2.39）mm/h]降低幅度更大（P<0.05）。觀察組總有效率為88.37%（38/43），對(duì)照組為69.77%（30/43），觀察組高于對(duì)照組（P<0.05）。觀察組不良反應(yīng)發(fā)生率為2.33%（1/43），對(duì)照組為13.95%（4/86），觀察組不良反應(yīng)率明顯比對(duì)照組低（P<0.05）。結(jié)論：與單純應(yīng)用坤復(fù)康片治療相比，聯(lián)合盆炎消止痛Ⅰ號(hào)方治療慢性盆腔炎更有顯著療效，可有效降低患者的盆腔炎性包塊面積和血液流變學(xué)指標(biāo)，緩解病狀，減少不良反應(yīng)的發(fā)生，提高治療總有效率，該方法安全可靠，具有較高的臨床推廣價(jià)值。

【關(guān)鍵詞】 盆炎消止痛Ⅰ號(hào)方； 慢性盆腔炎； 坤復(fù)康片； 臨床療效

【Abstract】 Objective：To observe the clinical curative effect of Panyanxiao ZhitongⅠcombined with Kunfukang Tablet on chronic pelvic inflammatory disease.Method：A total of 86 patients with chronic pelvic inflammatory disease admitted in our hospital from November 2015 to August 2016 were divided into the observation group and the control group according to digital parity method.The control group was treated with Kunfukang Tablets，the observation group was treated Panyanxiao Zhitong I combined with Kunfukang Tablets.During the treatment，the clinical symptoms of the patients were observed，pelvic inflammatory mass area and hemorheology changes of two groups were recorded.The adverse reaction of two groups were observed during treatment.The total effective rate of two groups were compared.Result：Before treatment，there were no statistical significance in pelvic inflammatory mass area and hemorheology indexes of two groups（P>0.05）.After treatment，pelvic inflammatory mass area and hemorheological indexes of two groups were both decreased，and pelvic inflammatory mass area and hemorheological indexes of the observation group[（4.30±2.23）cm2，（5.66±1.37）mm/h] were more lower than those of the control group[（8.66±2.32）cm2，（11.27±2.39）mm/h]（P<0.05）.The total effective rate of the observation group and the control group were 88.37%（38/43） and 69.77%（30/43），the total effective rate of the observation group was higher than that of the control group，the difference was statistically significant（P<0.05）.The adverse reaction rate of the observation group and the control group were 2.33%（1/43） and 13.95%（4/86），the adverse reaction rate of the observation group was significantly lower than that of the control group，the difference was statistically significant（P<0.05）.Conclusion：Compared with the simple application of Kunfukang Tablet，Panyanxiao ZhitongⅠand Kunfukang Tablet is more effective in treating chronic pelvic inflammatory disease，which can effectively reduce pelvic inflammatory mass area and hemorheology indexes，relieve the disease，reduce adverse reaction and improve the total effective rate of treatment，it is safe and reliable and has a high clinical value.endprint

【Key words】 Panyanxiao ZhitongⅠ； Chronic pelvic inflammatory disease； Kunfukang Tablet； Clinical efficacy

doi：10.3969/j.issn.1674-4985.2017.20.021

盆腔炎即盆腔炎癥性疾病（Pelvic inflammatory disease，PID）是指女性上生殖道及其周圍結(jié)締組織的炎癥，可局限于一個(gè)部位，也可同時(shí)累及多個(gè)部位，是婦女的常見病之一[1]。按有無合并癥可分為無合并癥盆腔炎和有合并癥盆腔炎。按其病程和臨床表現(xiàn)可分為急性盆腔炎和慢性盆腔炎兩種[2]。通常所說的慢性，是指由多個(gè)原因或疾病所致的盆腔疼痛性疾病的概括[3]。臨床上，慢性盆腔炎常表現(xiàn)為反復(fù)發(fā)作且經(jīng)久不愈，具有病程長(zhǎng)、復(fù)發(fā)率高的特點(diǎn)。盆腔炎未及時(shí)或未徹底治愈，就會(huì)發(fā)展成更難治、病程更長(zhǎng)的慢性盆腔炎，即盆腔炎性疾病后遺癥（Sequelae of Pelvic Inflammatory Disease，PIDS），不僅危害患者身心健康，還會(huì)增加患者家庭和社會(huì)的經(jīng)濟(jì)負(fù)擔(dān)[4]。有關(guān)……